Longitudinal monitoring of FVIII-binding antibodies and FVIII inhibitors in 2 representative examples of patients in subgroup 1. (A-B) Results of the analysis of FVIII-binding antibodies (IgG1, IgG2, IgG3, IgG4, IgA, IgM as indicated) and FVIII inhibitors (BU/mL) for 2 representative examples of patients in subgroup 1, patient 3 (A) and patient 6 (B), who did not develop FVIII inhibitors throughout the study period. The red dotted lines represent the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). The data for the remaining 5 patients of subgroup 1 are shown in supplemental Figure 2. B, baseline; ND, not detectable (below the detection limit of 1:20 for FVIII-binding antibodies).